Tempus AI

Tempus delivers insight generation at scale. Our comprehensive, AI-powered platform supports every stage of drug development—from discovery through commercialization. Heading to #ESMO26? Visit Booths #1068 & #1069 to connect with our team and explore our latest innovations. Learn more: https://tempus.co/4jFLmh3

Join us at #ESMO26 as we showcase novel clinical research revealing meaningful insights in cancer biology, treatment response, and patient outcomes. Visit us at booth #1068 & 1069 to experience live demos of our AI-powered technology and new product offerings designed to advance drug discovery and development. Learn more: https://tempus.co/4BeTOtI

October is #DysautonomiaAwarenessMonth. For patients living with dysautonomia, managing the condition often feels like a full-time job: organizing fragmented medical records, tracking unpredictable symptoms across disparate systems, and constantly repeating medical histories to multiple specialists. For Laura Elster, Chief Commercial Officer at Tempus, and her daughter Sophia, navigating this exact "triad" meant living with disjointed health data spread across multiple hospital networks. By turning to Olivia, our personal health concierge app, they were able to consolidate their complex, fragmented health histories into a single comprehensive timeline. Instead of tracking down test results and symptom logs, they now walk into appointments with an objective, data-backed summary, transforming passive waiting into proactive collaboration with their care team. Watch their full story to see how Olivia helps bring clarity to complex health journeys: https://lnkd.in/gwxN4X6R Explore Olivia here: https://lnkd.in/e3GmCaSv

Real-Time Variant Tracker™ (RTVT), is a feature now available as a part of xM (NeXT Personal ® Dx). RTVT delivers an added layer of clarity directly within the standard report clinicians already receive, including variants associated with NCCN guideline-recommended and FDA-approved therapies. These findings providing immediate, actionable context the moment an associated signal shifts.

In cancer care, getting patients onto the right treatment at the right time requires equipping care teams with timely, accurate diagnostic information. New data presented at #ESMO2026 from our collaboration with Pfizer demonstrates how AI helps make this possible in advanced #NSCLC by leveraging insights from routine H&E pathology images, already generated as part of care, to identify patients who may need confirmatory biomarker testing. AI-enabled pre-screening is designed to help clinicians prioritize diagnostic testing, increase the number of patients who receive appropriate biomarker testing, accelerate access to clinically actionable results and preserve limited tissue samples. Read on: https://tempus.co/3VYlcfu

We will report financial results for the third quarter ended September 30, 2026, before U.S. markets open on Monday, November 2, 2026. The live audio webcast will be accessible through the “Events” section of the Tempus Investor Relations website, as well as here: https://tempus.co/47USb73

We'll be at #ASCOQLTY26 presenting two abstracts demonstrating how Tempus Next uses agentic care-gap detection and AI-guided oncology care pathways to identify testing gaps and notify care teams. Stop by our poster sessions or connect with our team at the conference to learn more: https://tempus.co/4egjdJJ American Society of Clinical Oncology (ASCO) Chelsea Osterman, MD

We’re looking forward to seeing you at Pathology Visions '26 in San Diego. Stop by Booth #204 meet with the Tempus team and experience live demos of our digital pathology and AI offerings that enable biomarker prediction and workflow efficiency. Learn more: https://tempus.co/4i0IGYT Digital Pathology Association

We're proud to add to our offerings for patients with rare diseases. This offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges and improve the ability to find and interpret answers.

The initial days following an advanced cancer diagnosis are critical for treatment planning. With Tempus Preview, clinicians may access clinically relevant predictions within ~24 hours of sample receipt. These early insights empower clinicians to anticipate targeted treatment pathways and coordinate management plans, without altering standard tissue workflows. Tempus Preview provides preliminary predictions and treatment should not be initiated until confirmatory NGS results are received. Learn more: https://tempus.co/4hKurbM